
    
      Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who
      have been treated with olanzapine or risperidone for at least three months randomized to
      receive adjunctive treatment with a 5-HT1A agonist (buspirone, 15-30 mg/day)or placebo.
    
  